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Abstract
DNA double-strand breaks (DSBs) are highly toxic lesions, which, if not properly repaired, can give rise to genomic instability.
Non-homologous end-joining (NHEJ), a well-orchestrated, multistep process involving numerous proteins essential for cell
viability, represents onemajor pathway to repair DSBs in mammalian cells, andmutations in different NHEJ components have
been described in microcephalic syndromes associated, e.g. with short stature, facial dysmorphism and immune dysfunction.
By using whole-exome sequencing, we now identiﬁed in three affected brothers of a consanguineous Turkish family a
homozygous mutation, c.482G>A, in the XRCC4 gene encoding a crucial component of the NHEJ pathway. Moreover, we found
oneadditional patient of Swiss origin carrying the compoundheterozygousmutations c.25delG (p.His9Thrfs*8) and c.823C>T (p.
Arg275*) in XRCC4. The clinical phenotype presented in these patients was characterized by severe microcephaly, facial
dysmorphism and short stature, but they did not show a recognizable immunological phenotype. We showed that the XRCC4
c.482G>Amutation, which affects the last nucleotide of exon 4, induces defective splicing of XRCC4 pre-mRNAmainly resulting
in premature protein truncation and most likely loss of XRCC4 function. Moreover, we observed on cellular level that XRCC4
deﬁciency leads to hypersensitivity to DSB-inducing agents and defective DSB repair, which results in increased cell death after
exposure to genotoxic agents. Taken together, our data provide evidence that autosomal recessive mutations in XRCC4 induce
increased genomic instability and cause a NHEJ-related syndrome deﬁned by facial dysmorphism, primary microcephaly and
short stature.
Introduction
Maintenance of genomic integrity and the protection of DNA
against damage are important processes required for proper
cell function and survival. DNA damage can be caused by differ-
ent endogenous factors such as replication stress during prolifer-
ation or reactivemetabolites as well as by exposure to exogenous
factors such as UV light, radiation ormutagenic chemicals, and it
affects both proliferating and non-dividing, differentiated cells.
As the accumulation of DNA damage has an important impact
on cell viability, organisms have evolved various mechanisms
to protect the integrity of DNA by inducing DNA damage re-
sponses or triggering cell death. Among the different types of
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DNA damage, double-strand breaks (DSBs) belong to the most
cytotoxic and deleterious types, and two major DSB repair path-
ways are known to sense double-strand lesions and restore DNA
integrity: homologous recombination (HR) and non-homologous
end-joining (NHEJ) (1). HR is considered to be the more accurate
mechanism to repair DSBs, but it requires the presence of a prop-
er template to exchange and replace defective genetic informa-
tion (2). In contrast, NHEJ is generally considered to be more
prone to errors, but does not rely on a homologous template
like, e.g. sister chromatids (3,4). Whether HR or NHEJ is activated
to repair DSBs ismainly determined by the cell type, the cell cycle
phase and the DNA structure at the site of DNA break (5).
Several human congenital syndromes have been described
that are associated with defects in components involved in
NHEJ. These include mutations in the catalytic subunit of the
DNA-activated protein kinase (DNA-PKcs; encoded by PRKDC,
MIM 6 00 899) gene encoding the catalytic subunit of a nuclear
DNA-dependent serine/threonine protein kinase, which binds
to DNA DSBs and facilitates recruitment of other proteins to the
lesion, in the non-homologous end-joining factor 1 gene (NHEJ1,
MIM 6 11 290; also known as XLF and Cernunnos) and in the DNA
cross-link repair protein 1C (DCLRE1C, MIM 6 05 988; also known
as Artemis) gene. Furthermore, several mutations in the DNA lig-
ase IV gene (LIG4, MIM 6 01 837) have been identiﬁed, encoding an
ATP-dependent DNA ligase that catalyses the ﬁnal DNA ligation
step and is crucial for efﬁcient joining of DNA strands in NHEJ
(6–11). Individuals with autosomal recessive mutations in these
genes mainly present with severe immunodeﬁciency due to de-
fective V(D)J recombination during lymphocyte development, a
process depending on NHEJ, and show additional characteristics
like primary microcephaly, short stature and facial dysmorph-
ism. Very recently, it has been proposed that a homozygousmis-
sense mutation in XRCC4 causes severe microcephaly and short
stature, but since two other homozygous variants in other genes
were also present in this patient, the ﬁnal proof that recessive
XRCC4mutations are associated with amicrocephalic short-stat-
ure syndrome awaits conﬁrmation (12). XRCC4 forms a stable
complex with LIG4 during the repair of DNA DSBs by NHEJ, and
it has been shown that XRCC4 directly inﬂuences the joining ac-
tivity of LIG4 (13–16).
In this study, we report the identiﬁcation of novel homozy-
gous and compound heterozygousmutations inXRCC4 in a Turk-
ish family with three affected children and an individual of Swiss
origin presenting with short stature, microcephaly and intellec-
tual disability, and we show that disruption of XRCC4 induces
hypersensitivity toDSBs, defectiveDNADSB repair and increased
apoptosis after DNA damage.
Results
Clinical characteristics
The Turkish family FAM-01 was referred for genetic counselling
due to a congenital, likely autosomal recessive disorder in three
brothers born to consanguineous parents, who presented with
developmental delay, mild intellectual disability, pronounced
primary microcephaly and short stature. The clinical details of
the affected individuals are listed in Table 1. The affected broth-
ers also showed a typical facial gestalt characterized by a long,
beaked nose, mid-facial hypoplasia and mild hypotelorism
(Fig. 1A). At the last referral to the hospital, the brothers were
14 years of age (individual IV.1), 10.5 years of age (IV.2) and 6
months (IV.3). Head circumferences were −7.5 SD (IV.1), −6.5 SD
(IV.2) and −4.5 SD (IV.3) and height was also reduced in all three
sibs ranging from −3 to −5 SD (Table 1). MRI was available from
patient IV.1 and showed a simpliﬁed gyral pattern. In addition,
the two oldest sibs showed mild thrombocytopenia, but no add-
itional hematological abnormalities. No recurrent infections or
other signs for immunological problems were observed in any
of the affected individuals.
The index patient II.2 of family FAM-02 is the second child of
non-consanguineous Swiss parents andwas born spontaneously
after an uneventful pregnancy at 38 weeks of gestation. Family
history was unremarkable. Early motor milestones were normal
but speech development was mildly delayed. Short stature and
microcephaly were present from birth (Table 1; Fig. 2A and B).
The anterior fontanel was very small at birth (1 × 1 cm) and was
found closed at the age of 15 months. Bone age corresponded
to the chronological age at 10 years. Apart from malposition of
teeth, mild developmental delay and special education mainly
due to dyscalculia, clinical course was unremarkable. There
was no history of recurrent infections or vegetative problems.
Karyotyping after GTG banding and subtelomeric FISH studies re-
vealed normal results.
Identiﬁcation of homozygous and compound
heterozygous XRCC4mutations
Weperformedwhole-exome sequencing (WES) onDNAextracted
from blood lymphocytes of individual IV.1 of family FAM-01
using the NimbleGen SeqCap EZ Human Exome Library v2.0 en-
richment kit on an IlluminaHiSeq2000 sequencer.WES data ana-
lysis and ﬁltering of variants were carried out using the exome
analysis pipeline ‘Varbank’ of the Cologne Center for Genomics
(CCG, University of Cologne, Germany) and we obtained a mean
coverage of 106 reads, and 96.5% of targets were covered more
than 10×. After exclusion of homozygous or compound heterozy-
gous variants in any of the 13 OMIM-referenced genes associated
with autosomal recessive isolated or syndromic forms of primary
microcephaly, we applied the following criteria for ﬁltering of the
WES variants: coverage of more than six reads, a minimum qual-
ity score of 10, an allele frequency ≥75%, aminor allele frequency
(MAF) <0.5% in the 1000 Genomes database and the Exome Vari-
ant Server (EVS; NHLBI Exome Sequencing Project) and not anno-
tated in the in-house WES data sets of the CCG.
Using these ﬁlter criteria, we identiﬁed in total 16 homozy-
gous variants, 12 of them embedded in the 10 largest homozy-
gous regions (>8 Mb) determined from the WES data set. These
homozygous variants included four intronic variants predicted
to have minor to none inﬂuence on the adjacent splice-sites by
different splicing prediction programs, and 12 homozygous mis-
sense variants. Among these, only a single homozygous variant
was predicted to have a severe impact on protein function and to
be most likely deleterious. This variant, c.482G>A, was located at
the last nucleotide of exon 4 of theXRCC4 gene, and bioinformatic
analysis indicated that the G>A substitution has a severe impact
on the proper recognition of the adjacent donor splice-site.
The XRCC4 gene is embedded within a large homozygous
stretch of 21.2 Mb (located between positions chr5:73 931 246
and chr5:95 128 742) and the c.482G>A variant is predicted to
completely disrupt the donor splice-site of intron 4 of XRCC4.
We conﬁrmed the presence of the homozygous variant in patient
IV.1 as well as in the two siblings IV.2 and IV.3 by Sanger sequen-
cing and showed that both parents are heterozygous carriers
(Fig. 1B). Subsequent analysis of microsatellite markers in all
family members conﬁrmed homozygous haplotypes for the
identiﬁed region on chromosome 5 in all affected individuals
(Fig. 1C). Furthermore, the c.482G>A variant is not annotated in
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any current database of human genetic variations including
the 1000 Genomes Database, the Exome Variant Server [EVS,
National Heart, Lung and Blood Institute Exome Sequencing
Project (ESP), Seattle, WA, USA] and the >120 000 alleles of the
ExomeAggregation Consortium [ExomeAggregation Consortium
(ExAC), Cambridge, MA, USA] indicating that this is most likely
the causative mutation in the patients.
Additionally, we performed NGS-based sequencing of 4813
disease-associated genes on DNA extracted from blood lympho-
cytes of the index patient II.2 of family FAM-02 using the Tru-
Sight™ One Sequencing Panel on an Illumina HiSeq System.
We obtained an average depth of coverage of 145 reads and
94.2%of the targeted baseswere assessed by≥20 independent se-
quence reads, and we identiﬁed two heterozygous variants,
c.25delC (chr5:82 400 762) and c.823C>T (chr5:82 554 426), in
XRCC4. Sanger sequencing conﬁrmed both mutations in patient
II.2 and revealed that parents were each heterozygous carriers
for one of thesemutations: the c.25delCmutationwas paternally
inherited, and the c.823C>T mutation was inherited from
the mother (Fig. 2C). The c.25delC mutation is predicted to
cause a frameshift resulting in a severely truncated protein
(p.His9Thrfs*8), whereas the c.823C>T mutation introduces a
premature stop codon (p.Arg275*) in XRCC4.
The exonic c.482G>A mutation in XRCC4 affects
pre-mRNA splicing and protein stability
As the c.482G>A mutation identiﬁed in family FAM-01 was pre-
dicted to alter splicing of XRCC4 exon 4, we analyzed the effect
of this mutation on the XRCC4 transcript by RT–PCR and
Table 1.Clinical ﬁndings in individuals carrying the homozygous and compoundheterozygousXRCC4mutations comparedwith individualswith
LIG4 syndrome described by Murray et al. (11)
Patient IV.1 (FAM-01) IV.2 (FAM-01) IV.3 (FAM-01) II.2 (FAM-02) LIG4 patients
Sex Male Male Male Female
Mutation XRCC4 c.482G>A XRCC4 c.482G>A XRCC4
c.482G>A
XRCC4 c.25delC,
c.823C>T
LIG4 various mutations
Gestn/weeks 40 40 40 38 32 to 40
Birth weight −5.3 SD −2.8 SD −2.4 SD −3.5 SD −3.0 ± 0.93 SD
Birth OFC <−3 SD <−3 SD <−3 SD −3.7 SD −3.6 SD ± 1.37 SD
Birth length −2 SD Unknown Unknown −2.8 SD −3.8 ± 1.88 SD
Age at last
examination
14 years 10.5 years 6 months 14 years 10 months —
OFC/SD −7.5 SD −6.5 SD −4.5 SD −5.0 SD −10.1 ± 0.95 SD
Height/SD −5 SD −5 SD −3 SD −2.6 SD −5.1 ± 1.62 SD
Developmental
delay
Mild Mild Unknown Mild None to moderate
Developmental
milestones
Sitting at 6 months
walking at 12 months
Unknown Unknown Sitting at 6 months,
walking at 13 months,
Not described
Intellectual
disability
Mild intellectual
disability, could not
follow primary
school, normal daily,
practical, social and
communication skills
Mild intellectual
disability, could not
follow primary school,
normal daily,
practical, social and
communication skills
Mild
intellectual
disability
(no details
known)
Special education due to
dyscalculia; ability to
read and write;
normal adaptive
functioning with
personal
independence,
normal daily,
practical, social and
communication skills
Unknown
Speech
development
Delayed, starting single
words at 4 years
Unknown Unknown Delayed, ﬁrst words at
2.6 years
Unknown
Hematological
ﬁndings
Mild thrombocytopenia
(PLT 285.000, age 3
PLT 120.000, age 14)
Mild thrombocytopenia
(PLT 133.000, age 10)
Unknown Not noted Pancytopenia (onset 2–15
years) marked
thrombocytopenia
Immune
dysfunction
Not noted Not noted Not noted Not noted Hypo-/
agammaglobulinemia
Facial
dysmorphism
& Additional
features
Long face with
prominent chin, long
and beaked nose,
high nasal bridge,
sloping forehead,
mild hypotelorism
Long face with
prominent chin, long
and beaked nose, high
nasal bridge, sloping
forehead, mild
hypotelorism,
undescended testes
Beaked nose,
high nasal
bridge,
sloping
forehead,
inguinal
hernia
Long face with
prominent chin,
prominent and long
philtrum, prominent
columella, high nasal
bridge, deep set eyes,
mild strabism, high
forehead, long neck,
malpositioning of
teeth, excessive white
lines on palms, mild
truncal obesity
wide nasal bridge, broad
nasal tip and a
prominent chin,
sloping forehead, ﬁne
sparse hair
MRI ﬁndings Simpliﬁed gyral pattern Unknown Unknown Not performed Unknown
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subsequent Sanger sequencing of PCR fragments (Fig. 3). In con-
trast to wild-type cDNA, we observed three major XRCC4 tran-
scripts from cDNA of the index patient IV.1: (i) a major
transcript generated by complete skipping of exon 4 of XRCC4
predicted to cause a frameshift and premature truncation of
the protein (p.Phe106Ilefs*1), (ii) a minor transcript generated
by complete skipping of exons 3 and 4 of XRCC4, also predicted
to cause a frameshift and premature truncation of XRCC4 protein
(p.Val47Aspfs*5) and (iii) a correctly spliced minor transcript car-
rying the p.Arg161Gln missense mutation. Both, deletion of exon
4 and skipping of exons 3 and 4 are predicted to result in a frame-
shift and premature protein truncation deleting large, highly
conserved parts of the protein suggesting most likely complete
loss of XRCC4 protein function for these two aberrant transcripts.
To further investigate the impact of the c.482G>Amutation on
protein function and stability, we analyzed the expression of
XRCC4 in primary ﬁbroblasts established from index patient
IV.1 of family FAM-01 (hereinafter referred to as XRCC4-ﬁbro-
blasts) and from an age- and sex-matched healthy control indi-
vidual. Western blot analysis demonstrated a severe reduction
of full-length XRCC4 protein in XRCC4-ﬁbroblasts compared
with wild-type cells, consistent with the results obtained by
RT–PCR analysis (Fig. 4A). Still, we also detected a faint band of
corresponding size to wild-type XRCC4, which most probably re-
presents the full-length XRCC4 carrying the p.Arg161Gln mis-
sense mutation. Furthermore, we did not observe any protein
expression of the truncated XRCC4 forms in patient ﬁbroblasts
implying protein instability and complete loss of function of
these truncated XRCC4 variants.
For detailed analysis of protein stability, we cloned wild-type
and mutant XRCC4 cDNA mimicking the most prominent tran-
script identiﬁed in the index patient IV.1 (family FAM-01)
(XRCC4 p.Phe106Ilefs*1) into a mammalian expression vector
with a C-terminal FLAG tag. Whereas transfection of HEK293T
cells with wild-type XRCC4 resulted in detection of recombinant,
FLAG-tagged protein, wewere not able to detect expression of the
p.Phe106Ilefs*1 mutant protein (Fig. 4B). Moreover, treatment of
cells with MG-132, a potent inhibitor of the ubiquitin-dependent
proteasome system, did also not result in detection of residual
mutant protein, which suggests that either no truncated XRCC4
protein is expressed or different pathways are utilized for its im-
mediate degradation.
XRCC4-ﬁbroblasts are hypersensitive to DSB-inducing
agents
XRCC4 is a ubiquitously expressed protein that is involved in the
repair of DNA DSBs. Together with LIG4, XRCC4 forms a complex
which plays a crucial role in the ﬁnal ligation step of DNA DSB re-
pair via NHEJ (13–16). To further characterize the effects of XRCC4
deﬁciency on DNA damage response pathways and DNA repair,
we treated XRCC4-ﬁbroblasts either with UV light [in order to in-
duce nucleotide excision repair (NER) mediated DNA repair], or
etoposide (to activate DNA DSB repair) andmonitored the activa-
tion ofH2AX,which occurs rapidly after exposure toDNAdamage
and represents a sensitive marker for DNA damage and subse-
quent repair of DNA lesions (17). Whereas we could not observe
any differences in the activation of H2AX after irradiation of
Figure 1. Clinical and molecular characterization of the Turkish family FAM-01. (A) Facial characteristics of affected siblings IV.1, IV.2 and IV.3 presenting with primary
microcephaly, long and prominent nose, and mild hypotelorism and synophrys in individuals IV.1 and IV.2. (B) Electropherograms of the identiﬁed XRCC4 mutation
conﬁrmed the homozygous missense mutation, c.482G>A, in XRCC4 in all affected siblings while both parents were heterozygous carriers. (C) Pedigree of the
consanguineous Turkish family FAM-01 and haplotypes of 12 microsatellite markers surrounding XRCC4 on chromosome 5. Chromosomal location of XRCC4 is
depicted by black arrow. All three siblings are affected (solid symbols) while both parents are unaffected (white symbols). Asterisk indicates index patient IV.1, who
was subjected to whole-exome sequencing.
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wild-type and patient cells with UV light, XRCC4-ﬁbroblasts
showed a marked sensitivity to etoposide treatment and re-
sponded with hyperphosphorylation of H2AX (Fig. 5A). To ana-
lyze the cellular response to DNA DSBs in detail, we treated
cells with the radiomimetic chemical zeocin, which belongs to
the bleomycin family of antibiotics and has been shown to specif-
ically induce DNADSBs. Treatment ofXRCC4-ﬁbroblastswith low
doses of zeocin resulted in a signiﬁcant activation of H2AX in
XRCC4-ﬁbroblasts, whereas wild-type cells did not show any
H2AX activation (Fig. 5B). Moreover, treatment with higher con-
centrations of zeocin induced hyperphosphorylation of H2AX in
XRCC4-ﬁbroblasts comparable to that seen after etoposide treat-
ment. We next analyzed the activation of H2AX by ﬂow cytome-
try in detail and observed an increased and prolonged H2AX
activation after etoposide treatment inXRCC4-ﬁbroblasts indicat-
ing that disruption of XRCC4 reduces DNA DSB repair ability and
pointing towards a very critical function of XRCC4 during these
processes (Fig. 5C).To analyze the formation and repair of DNA
DSBs in more detail, we performed a neutral comet assay and
quantiﬁed the amount of DSBs in wild-type and XRCC4-ﬁbro-
blasts after etoposide treatment. In the the neutral comet assay
the extension of tailing, measured by the tail moment, correlates
with the appearance of DSBs. Using this method we were able to
assess the amount ofDSBs and thereby the efﬁciencyofDSB repair
in XRCC4-ﬁbroblasts. Interestingly, we did not observe any differ-
ences in the tail moment comparing untreated wild-type and
XRCC4-cells suggesting that either residual XRCC4 p.Arg161Gln is
sufﬁcient to handle low levels ofDSBsproduced bynormal cellular
processes or that these lesions can be repaired independently of
XRCC4. However, after etoposide treatment, the occurrence of
DSBs in XRCC4-ﬁbroblasts was signiﬁcantly higher compared
with wild-type cells (Fig. 6A and B) conﬁrming the important
role of fully functional XRCC4 in the repair of these DNA lesions.
DNA DSBs are one of themost cytotoxic forms of DNA lesions
and the repair of DSBs is crucial for the maintenance of genomic
integrity. If unrepaired, DSBs can induce apoptosis and, thereby,
give rise to increased cell death. In order to investigate the impact
of unrepaired DSBs on cell viability and survival, we analyzed the
cytotoxicity of exposure to etoposide by MTT assay (Fig. 6C). We
observed a signiﬁcantly higher cytotoxicity in XRCC4-ﬁbroblasts
comparedwithwild-type cells suggesting that functional impair-
ment of XRCC4 does not only directly affect DSB repair, but fur-
thermore results in the induction of cell death if DNA lesions
remain unrepaired.
Figure 2. Clinical and molecular characterization of index patient II.2 of the Swiss family FAM-02. (A) Facial characteristics of index patient II.2 presenting with primary
microcephaly, long facewith prominent chin, highnasal bridge, andmild strabism. (B) Pedigree of thenon-consanguineous Swiss family FAM-02. (C) Electropherogramsof
identiﬁed compound heterozygous XRCC4 mutations, c.25delC and c.823C>T, compared with wild-type (Control) sequences and heterozygous carrier sequences of the
father (I.1), mother (I.2).
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Discussion
Here, we show that mutations in XRCC4 are associated with pri-
marymicrocephaly, facial dysmorphism and short stature. More-
over, we show that the identiﬁed mutations mainly lead to
premature protein truncation and protein instability resulting
in hypersensitivity to DNA DSBs, retarded DSB repair and in-
creased cell death in XRCC4-ﬁbroblasts.
XRCC4 is an essential factor in NHEJ, which is one of two
major pathways for the repair of DNA DSBs in mammalian cells
(1). It can directly bind to DNA and it forms a stable complex to-
gether with the DNA ligase IV, which localizes to the broken DNA
ends. XRCC4 stimulates and inﬂuences the joining activity of
LIG4 directly and indirectly due to its interaction and recruitment
ofNHEJ1, an additional protein regulating LIG4 activity (1,8,18,19).
Previous studies indicate that NHEJ is the predominant path-
way for the repair of DNA DBSs in differentiated neuronal cells
(20). As HR relies on the presence of suitable homologous tem-
plates like sister chromatids, NHEJ is the only appropriate path-
way to repair DSBs in non-dividing, differentiated neurons.
Additionally, neurons display a high metabolic rate probably
thereby giving rise to an increased production of reactive meta-
bolites like ROS, which, for example, can cause DNA damage.
An efﬁcient DNA repair machinery is therefore important to re-
pair these kinds of lesions. Complete knockout of NHEJ key fac-
tors leads to extensive cell death in neuronal tissue resulting in
embryonic lethality as shown in different animal models. In ac-
cordance with these observations patients with recessive muta-
tions in LIG4, NHEJ1 or PRKDC present, e.g. with severe primary
microcephaly often associated with seizures, simpliﬁed gyral
pattern and short stature (7,8,10,11,21,22). Consistent with
these studies, all patients presented here showed a typical
NHEJ-related phenotype deﬁned by marked microcephaly,
typical facial dysmorphism, developmental delay andmild intel-
lectual disability. Interestingly, we did not observe any immuno-
deﬁciency in any of the affected individuals, which is in linewith
a previously reported patient presenting with microcephaly and
Figure 3. RT–PCR analysis of XRCC4 transcripts. (A) Schematic representation of the ampliﬁed region of XRCC4 cDNA and locations of primers used for the ampliﬁcation.
The black arrow indicates the position of the c.482G>Amutation in exon 4. (B) RT–PCR analysis ofXRCC4 in individual IV.1 showed three different transcripts (Mut 1–3): two
alternative transcripts of smaller size, and one transcript of corresponding size compared with WT (Mut 1). Sequencing of the WT and Mut 1–3 RT–PCR products
determined the exon composition of all transcripts showing that the c.482G>A mutation mainly leads to alternatively spliced XRCC4 pre-mRNA. Lower left panel:
Functional consequences of impaired XRCC4 pre-mRNA splicing on protein level. The main splicing product characterized by exon 4 skipping induces a frameshift
and premature protein truncation (Mut 2, p.Phe106Ilefs*1). A second splicing product generated by skipping of exons 3 and 4 is predicted to cause a truncated protein
of 51 amino acids (Mut 3, p.Val47Aspfs*5). Additionally, we observed a correctly spliced XRCC4 transcript resulting in translation of a mutant XRCC4 protein carrying a
missense mutation (Mut 1, p.Arg161Gln). The red line indicates the position of the substituted amino acids in XRCC4 (grey box). Hatched areas represent the missing
parts in the truncated proteins.
Figure 4.The c.482G>Amutation inXRCC4 alters protein stability. (A) Upper panel:
western blot analysis of XRCC4 expression in wild-type (WT) and patient
ﬁbroblasts (XRCC4) established from individual IV.1 revealed a strong reduction
in XRCC4 expression in cells carrying the c.482G>A mutation. No truncated
forms of XRCC4 were detectable in patient cells. Lower panel: equal protein
loading was conﬁrmed by re-probing of the membrane with antibodies against
actin. (B) HEK293T cells were transfected with FLAG-tagged wild-type XRCC4
(WT), XRCC4 p.Phe106Ilefs*1 (Mut) or empty vector as control (Ctr). Cells were
either treated with the proteasome inhibitor MG-132 (+) or left untreated (−).
Cells were lysed, and whole cellular lysates (WCL) were subjected to western
blot analysis with anti-FLAG antibodies. No truncated form of XRCC4 could be
detected before or after treatment of cells with MG-132.
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short stature due to amissense alteration inXRCC4 (12). However,
it remains unclear whymutations in XRCC4 do not cause any ob-
servable immunological defects as it is well known that NHEJ
plays an essential role in V(D)J-recombination during B- and
T-cell maturation, and mutations in other key factors of NHEJ
like LIG4, PRKDC and DCLRE1C lead to moderate-to-severe
Figure 5.XRCC4-ﬁbroblasts are hypersensitive to DSB-inducing agents. (A) Western blot analysis of UV- and etoposide-induced phosphorylation of H2AX (Ser139).XRCC4-
ﬁbroblasts (XRCC4) andwild-type cells (WT) were treatedwith UV-C or etoposide, lysed and subjected towestern blot analysis. Equal protein loading was conﬁrmed by re-
probing of the membrane with antibodies against H2AX and actin. (B) Western blot analysis of zeocin-induced phosphorylation of H2AX (Ser139). XRCC4-ﬁbroblasts
(XRCC4) and wild-type cells (WT) were treated with 5 µg/ml (left panel) or 50 µg/ml (right panel) zeocin, lysed and subjected to western blot analysis. Equal protein
loading was conﬁrmed by re-probing of the membrane with antibodies against H2AX and actin. (C) FACS analysis of wild-type (blue) and XRCC4-ﬁbroblasts (red) after
exposure to etoposide for 1 h. Cells were harvested 1, 5 and 24 h after treatment. Untreated cells (0 h) were used as controls. While untreated wild-type and XRCC4-
ﬁbroblasts do not show differences in basal H2AX activation, treatment with etoposide induced a signiﬁcant increase in γH2AX levels in XRCC4-ﬁbroblasts compared
with wild-type cells.
Figure 6. The c.482G>A mutation in XRCC4 impairs DSB repair. (A) Representative images of wild-type (WT) and XRCC4-ﬁbroblasts (XRCC4) analysed by neutral comet
assay. (B) Quantiﬁcation of tail moments in wild-type (WT) and XRCC4-ﬁbroblasts (XRCC4) after treatment with etoposide for 1 h, followed by a repair period of 1 h and
subsequent analysis via neutral comet assay. The tail moment (|percentage of DNA content in tail| × |tail length|) was used to evaluate DNA damage and repair efﬁciency.
The displayed data indicate that the tail moment is signiﬁcantly increased in XRCC4-ﬁbroblasts compared with wild-type cells (P-value = 0.0092). Statistical signiﬁcance
was analysed using paired Student’s t-test. Error bars represent SD. n = 3. **P-value < 0.01. (C) MTT assay of wild-type (WT) and XRCC4-ﬁbroblasts (XRCC4) after treatment
with etoposide for 1 hour and analysis 72 h later. Untreated cells were used throughout the experiments as controls. Three different wild-type cell lines were analysed in
triplicates during each experiment and values were pooled afterwards for graphical presentation. The cytotoxicity is increased in XRCC4-ﬁbroblasts compared with wild-
type cells (P-value = 0.0072). Statistical signiﬁcance was analysed using paired Student’s t-test. Error bars represent SD. n = 4. **P-value < 0.01.
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immunodeﬁciency (6–11). In contrast to the phenotype observed
in humans with mutations in XRCC4, examination of fetal thymi
isolated from Xrcc4 knockout mice showsmarkedly reduced size,
and both, B and T-cell development is arrested in early stages in
these animals (22). It remains possible that an immunological
phenotype might occur later in life in patients with XRCC4
mutations.
Our analysis of the functional consequences of the c.482G>A
mutation identiﬁed in family FAM-01 showed that this substitu-
tion in exon 4 most abundantly induces aberrant XRCC4 splicing
resulting in the generation of differently truncated XRCC4 var-
iants. However, we also observed a small portion of correctly
spliced transcript carrying the p.Arg161Gln missense mutation
in XRCC4. Thus, the identiﬁed mutation in XRCC4 is likely hypo-
morphic. Still, we can only speculate, if the residual full-length
protein carrying the p.Arg161Gln mutation is functional or not.
The argenine at position 161 is not verywell conserved and there-
fore, some residual XRCC4 activity is likely to be present, which
possibly explains the phenotypic difference between the knock-
out mousemodel and the patients presented in this study. In the
index patient II.2 of family FAM-02, we identiﬁed compound het-
erozygous truncating mutations, c.25delC and c.823C>T, in
XRCC4. The paternally inherited c.25delC deletion is predicted
to cause an early frameshift at p.His9 and most likely a complete
loss of protein function. The c.823C>T mutation, which was in-
herited by the mother, induces a premature protein truncation
at the very end of the protein (p.Arg275*). Especially, the evolu-
tionarily highly conserved LIG4-binding site in XRCC4 is still pre-
sent, possibly enabling at least partial functionality of the XRCC4
p.Arg275* protein.
Notably, it has been shown that LIG4- and PRKDC-deﬁcient
patients also exhibit hypomorphic mutations in LIG4 and
PRKDC, respectively, which provide residual protein function
(6,7,10,11). Like Xrcc4, knockout of Lig4 in mice is embryonically
lethal suggesting that complete loss of function mutations of
LIG4 and XRCC4 may not be compatible with life in humans
(21–23). Moreover, biochemical and cellular studies revealed
that mutations identiﬁed in LIG4 vary in their impact on LIG4
enzymatic activity with earlier truncating mutations being
more severe than mutations at the C-terminal end of LIG4
(24–27). Interestingly, these observations correlate with the
disease severity observed in humans with ‘early’ truncating
mutations having the most severe phenotype, while truncat-
ing mutations at the C-terminus of LIG4 cause a less severe
phenotype (11).
Finally, at a cellular level, we could show that mutations in
XRCC4 induce a marked sensitivity to DSB-inducing agents, and
that DSB repair occurs at a lower efﬁciency compared with
wild-type cells. Consistent with our results, previous studies
using XRCC4- and LIG4-knockout cell lines revealed similar re-
sults. LIG4- andXRCC4-deﬁcient cells exhibited an increased sen-
sitivity to ionizing radiation or treatment with DSB-inducing
chemicals resulting in slower kinetics of DSB repair and drastic-
ally reduced survival after treatment (22,28,29). Interestingly, in
line with our observation, UV-C induced DNA damage response
was not altered in cells lacking XRCC4 (30).
In summary, our data provide evidence that hypomorphic,
autosomal recessive mutations in XRCC4 cause a NHEJ-related
syndrome deﬁned by facial dysmorphism, primary microceph-
aly and short stature, but without immunological phenotype.
Moreover, we observed that XRCC4-deﬁciency leads to hyper-
sensitivity to DSB-inducing agent and defective DSB repair,
which results in increased cell death after exposure to genotoxic
agents.
Materials and Methods
Subjects
The study was performed in accordance with the Declaration of
Helsinki protocols and was approved by the Ethic Committee of
the University Hospital Cologne, Germany. Peripheral blood sam-
ples from the affected children and parents were collected after
written informed consent was obtained according to the proto-
cols approved by the participating institutions. Written consent
for publication of the photographs was given. DNA from partici-
pating familymemberswas extracted fromperipheral blood lym-
phocytes by standard extraction procedures.
NGS-based sequencing approaches
Whole-exome sequencing was performed on the index patient
IV.1 of family FAM-01. Exonic and adjacent intronic sequences
were enriched from genomic DNA using the NimbleGen SeqCap
EZHuman Exome Library v2.0 enrichment kit andwere run on an
Illumina HiSeq2000 sequencer by the Cologne Center for Genom-
ics (CCG). Data analysis and ﬁltering of mapped target sequences
was performed with the ‘Varbank’ exome and genome analysis
pipeline v.2.1 (CCG) and datawere ﬁltered for high-quality (cover-
age of more than six reads, a minimum quality score of 10), rare
(MAF < 0.5%) autosomal recessive variants. A disease-associated
gene panel was performed on DNA of the index patient II.2 of
family FAM-02 using the TruSight™ One Sequencing Panel
(4813 genes included, Illumina)with paired-end sequencing (Tru-
Seq Rapid Kit, 150 Fwd-150 Rev) on a Illumina HiSeq System. The
average depth of coverage was ×145 and about 94.2% of the tar-
geted bases were assessed by ≥20 independent sequence reads.
Mutation screening
Variants identiﬁed by NGS-based approaches were ampliﬁed
from DNA of the index patients and PCR products were se-
quenced by BigDye Terminator method on an ABI PRISM® 3100
Avant Genetic Analyzer (Life Technologies, Germany). Identiﬁed
mutations were re-sequenced in independent experiments and
tested for co-segregation within the families.
Microsatellite marker analysis
Microsatellite markers of three affected individuals of family
FAM-01 (IV.1, IV.2 and IV.3) and their parents (III.1 and III.2)
were genotyped using the ABI PRISM® 3100 Avant Genetic Ana-
lyzer and GeneScan® 3.7 software (Life Technologies, Germany).
Primer sequences to amplify speciﬁc markers were taken from
the UCSC genome browser (http://www.genome.ucsc.edu) and
primers were designed according to the reference sequences. Pri-
mers are available on request.
cDNA analysis
RNA was extracted from wild-type and ﬁbroblasts derived from
index patient IV.1 of family FAM-01 using the RNeasy Mini Kit
(Qiagen, Germany) and following manufacturer’s instructions.
RNA was reverse transcribed using the RevertAid™ First Strand
cDNA Synthesis Kit (Thermo Fisher Scientiﬁc, Germany). Primers
were designed according to the XRCC4 reference sequence and
ampliﬁed PCR products were separated on an agarose gel, puri-
ﬁed using the QIAquick Gel Extraction Kit (Qiagen, Germany)
and prepared for sequence analysis.
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Generation of wild-type and mutant XRCC4 expression
constructs
Generation ofwild-type (RefSeqNM_022406; NP_071801) andmu-
tant XRCC4 expression plasmid containing coding sequences of
humanXRCC4with an additional, C-terminal FLAG tagwas amp-
liﬁed by RT–PCR from isolated ﬁbroblast RNA and cloned into the
pcDNA3.1 expression vector (Life Technologies, Germany). All
cDNA sequences were conﬁrmed by Sanger sequencing.
Cell lines and cell cultures
HEK293T cells and primary ﬁbroblast cell lines established from
patient VI.1 of family FAM-01 were cultured in Dulbecco’s modi-
ﬁed Eagle medium (DMEM, Gibco) supplemented with 10% fetal
calf serum (FCS, Gibco), and antibiotics. For H2AX activation,
cells were either irradiated with 100 J/m2 UV-C or treated with
50 µ etoposide (Sigma-Aldrich, USA), 5 µg/ml or 50 µg/ml zeocin
(Invivogen, France) for 1 h. Drugs were then washed out, fresh
media was added and cells were incubated for the indicated
times and then subjected to western blot or FACS analysis.
HEK293T cells were transfected with 2 µg of each plasmid by
using Fugene® HD Transfection reagent (Promega, Germany) fol-
lowing manufacturer’s instructions and cells were solubilized
24 h post-transfection.
Protein isolation and analysis
Cells were solubilized by using ice-cold RIPA buffer [10 m Tris,
pH: 8.0; 150 m NaCl; 1 m EDTA; 10 m NaF; 1 m Na3VO4;
10 µM Na2MoO4; 1% NP-40; protease inhibitors P 2714 (Sigma-Al-
drich, USA)]. The total protein concentration of extracts was de-
termined using the BCA Protein Assay Kit (Thermo Fisher
Scientiﬁc, USA). 13–25 µg of total cell lysates were separated by
4–12% SDS–PAGE (Invitrogen, Germany) and blotted onto nitro-
cellulose membranes (GE Healthcare, Germany). Protein detec-
tion was performed using phospho-speciﬁc antibodies to
γH2AX (Ser139) (Cell Signaling Technology, USA). Antibodies to
H2AX were purchased from Calbiochem (USA). Anti-β-Actin,
anti-FLAG and anti-XRCC4 antibodies were purchased from
Sigma-Aldrich. Secondary antibodies conjugated to peroxidase
(Santa Cruz Biotechnology Inc., USA) were used and blots were
developed using an enhanced chemiluminescence system, ECL
Plus (GE Healthcare), followed by detection on autoradiographic
ﬁlms.
Neutral comet assay
Neutral comet assay was performed as described previously (31).
In brief, cells were incubated with 50 µ etoposide (Sigma-Al-
drich, USA) for 1 h, washed once with PBS and incubated for 1 h
to enable DNA repair. Cells were harvested in PBS and diluted
to 2 × 104 cells/ml. Frosted-end microscope slides were pre-
coated with 1% low-gelling-temperature agarose (LGTA). Four
hundred microliters of cell suspension was mixed with 1 ml
pre-heated 1% LGTA, pipetted on pre-coated slides and air-
dried for 2 min. Slides were submerged in N1 buffer [2% sarkosyl,
0.5 M Na2EDTA, 0.5 mg/ml proteinase K (pH 8)] and incubated for
18–20 h at 37°C followed by three washing steps with N2 buffer
[90 m Tris buffer, 90 m boric acid, 2 m Na2EDTA (pH 8.5)]
for 30 min at room temperature. Samples were submerged in
an electrophoresis chamber containing N2 buffer and a voltage
of 1.4 V/cm was applied for 25 min. Slides were washed with dis-
tilled water and incubated in 2.5 µg/ml propidium iodide (Sigma-
Aldrich, USA) in distilled water for 20 min. Finally, samples were
washed with distilled water and stored until analysis in a light
tight box at 4°C. Comets were visualized with the IX81 micro-
scope (Olympus, Germany) and an average comet tail moment
(|percentage of DNA content in tail| × |tail length|) was calculated
for at least 70 nuclei per slide using the CaspLab software (32).
MTT assay
Wild-type andXRCC4-ﬁbroblastswere either stressedwith 75 µ
etoposide (Sigma-Aldrich, USA) for 1 h or remained untreated.
Seventy-two hours after treatment, cells were incubated at 37°
C for 2 h in 5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (Sigma-Aldrich, USA) in PBS. The super-
natant was replaced by DMSO (AppliChem, Germany) and
plates were shaken at 225 rpm and 37°C for 5 min. The read-
out was performed by using the TECAN Saﬁre 2 microplate read-
er (TECAN, Germany) at 595 nm. The percentage of cytotoxicity
was calculated as described previously (33) and each measure-
ment was performed in triplicates with three different wild-
type ﬁbroblast cell lines and ﬁbroblast cells established from
index patient IV.1.
FACS analysis
Untreated or etoposide treated cells were harvested by trypsini-
zation, washed with 1% BSA/PBS and subsequently PBS, ﬁxed in
70% ethanol and stored at −20°C. For staining, cells were rehy-
drated in 1%BSAand 1%TritonX-100 in PBS, incubated for 10 min
on ice and afterwards for 1 h in 1% powdered milk/PBS at room
temperature. Samples were incubated for 2 h with anti-γH2AX
(Ser139) antibodies (Cell Signaling Technology, USA), sub-
sequently washed with PBS, monitored on a FACSCanto ﬂow
cytometer (Becton Dickinson, USA) and analyzed with FlowJo
(Tree Star, USA).
Web Resources
The URLs for data presented herein are as follows: ENSEMBL (ac-
cessed February 2015), http://www.ensembl.org, UCSC Genome
Browser (accessed February 2015), http://www.genome.ucsc.
edu, OnlineMendelian Inheritance inMan (OMIM) (accessed Feb-
ruary 2015), http://www.ncbi.nlm.nih.gov/omim, PolyPhen (ac-
cessed February 2015), http://genetics.bwh.harvard.edu/pph/,
Exome Variant Server (EVS) (accessed February 2015), http://evs.
gs.washington.edu/EVS, Exome Aggregation Consortium (ExAC)
(accessed April 2015), http://exac.broadinstitute.org/.
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